News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
594,798 Results
Type
Article (41846)
Company Profile (119)
Press Release (552833)
Section
Business (174291)
Career Advice (2507)
Deals (31134)
Drug Delivery (88)
Drug Development (75716)
Employer Resources (145)
FDA (14302)
Job Trends (13192)
News (301658)
Policy (29306)
Tag
Academia (2607)
Africa (779)
Alliances (42960)
Alzheimer's disease (1172)
Approvals (14224)
Arizona (120)
Artificial intelligence (64)
Asia (35833)
Australia (7004)
Bankruptcy (319)
Best Places to Work (10255)
Biosimilars (61)
Biotechnology (90)
C2C Services and Suppliers (63727)
California (1581)
Canada (864)
Cancer (405)
Career advice (2109)
Cell therapy (115)
China (129)
Clinical research (59192)
Collaboration (121)
Colorado (62)
Connecticut (64)
COVID-19 (2445)
Cystic fibrosis (65)
Data (220)
Diabetes (76)
Diagnostics (5724)
Drug pricing (65)
Earnings (64484)
Employer resources (130)
Europe (79244)
Events (88232)
Executive appointments (142)
FDA (14491)
Florida (228)
Funding (124)
Gene therapy (90)
GLP-1 (511)
Government (4136)
Healthcare (17084)
Hotbed/Location (401557)
Illinois (218)
Indiana (134)
Infectious disease (2470)
Inflammatory bowel disease (90)
Interviews (526)
IPO (13928)
Job creations (3024)
Job search strategy (1752)
Kansas (82)
Layoffs (380)
Legal (6601)
Liver cancer (56)
Lung cancer (97)
Manufacturing (81)
Maryland (349)
Massachusetts (1199)
Medical device (11300)
Medtech (11304)
Mergers & acquisitions (17059)
Metabolic disorders (238)
Michigan (129)
Minnesota (175)
Neuroscience (1316)
New Jersey (494)
New York (525)
NextGen Class of 2024 (5886)
Non-profit (4158)
North Carolina (556)
Northern California (726)
Obesity (135)
Ohio (90)
Opinion (190)
Patents (67)
Pennsylvania (459)
People (53755)
Phase I (18154)
Phase II (25949)
Phase III (19964)
Pipeline (105)
Policy (57)
Postmarket research (2425)
Preclinical (7502)
Press Release (72)
Rare diseases (125)
Real estate (4916)
Recruiting (56)
Regulatory (19453)
Research institute (2210)
Resumes & cover letters (368)
South America (1064)
Southern California (677)
Startups (3029)
Texas (195)
United States (7225)
Vaccines (447)
Washington State (220)
Weight loss (124)
Date
Today (94)
Last 7 days (612)
Last 30 days (2003)
Last 365 days (34579)
2024 (23916)
2023 (36922)
2022 (47874)
2021 (51588)
2020 (49988)
2019 (42771)
2018 (32536)
2017 (29804)
2016 (28711)
2015 (33866)
2014 (26262)
2013 (21668)
2012 (22920)
2011 (24136)
2010 (21976)
594,798 Results for "aravive biologics formerly known as ruga corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
Baxter International Inc. announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.
May 29, 2024
·
5 min read
Business
Aravive Reports First Quarter 2023 Financial Results and Provides Corporate Updates
Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported first quarter 2023 financial results and provided corporate updates.
May 10, 2023
·
12 min read
Drug Development
AltruBio Raises $225M in Series B to Advance Ulcerative Colitis Candidate
Formerly known as AbGenomics Holding, AltruBio on Tuesday said it will use the funds to push its ulcerative colitis asset into a Phase IIb trial with an anticipated readout in 2026.
May 21, 2024
·
2 min read
·
Tyler Patchen
Spur Therapeutics (Formerly Freeline) Announces New Name and Brand
Spur Therapeutics, formerly Freeline Therapeutics, today announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine.
June 17, 2024
·
5 min read
Policy
Aravive, Inc. to Delist from The Nasdaq Stock Market - Jan 17, 2024
Aravive, Inc., announced that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select Market and, based upon ownership of its shares by fewer than 300 holders of record, deregister its common stock under the Securities Exchange Act of 1934, as amended and suspend its public reporting obligations.
January 17, 2024
·
3 min read
Genetown
Sapphiros and Cencora, formerly AmerisourceBergen Corporation, Enter into Distribution Agreement
Sapphiros is proud to announce it has entered into a distribution agreement with Cencora, Inc. (NYSE: COR), formerly AmerisourceBergen Corporation.
November 22, 2023
·
2 min read
Deals
Advanced Biologics Elevates Biologic Innovations Through Merger with Isto Biologics.
Advanced Biologics (known commercially as Biologica Technologies), a California-based company known for their innovative biologic solutions, announced today their successful merger with Isto Biologics, a global leader in regenerative and autologous therapies.
October 18, 2023
·
3 min read
Drug Development
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
89bio, Inc. today announced the initiation of its Phase 3 ENLIGHTEN Program evaluating the efficacy and safety of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH).
March 12, 2024
·
8 min read
Biotech Bay
Lykos Therapeutics (Formerly MAPS PBC) Announces Publication Examining the Effects of MDMA-Assisted Therapy on Emotional Coping Skills and Self-Experience in PTSD
Lykos Therapeutics (formerly MAPS Public Benefit Corporation) (“Lykos”) announced that PLOS ONE has published the first comparison of the effects of investigational MDMA-assisted therapy and therapy with placebo on emotional coping skills and self-experience in adults with severe post-traumatic stress disorder (“PTSD”).
January 10, 2024
·
9 min read
Lone Star Bio
Aravive Announces Poster Presentation on Batiraxcept at 2023 ASCO Annual Meeting
Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of a poster featuring batiraxcept data in clear cell renal cell carcinoma at the upcoming American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, being held June 2-6, 2023 in Chicago, Illinois and virtually.
April 26, 2023
·
2 min read
1 of 59,480
Next